Category: Wall Street Beat
Standard & Poor's Ratings Services maintains a credit watch on Medtronic over its $43 billion buyout of Covidien, pending Medtronic's ability to control its indebtedness.
Covidien snaps up Reverse Medical and its line of vascular devices for an unspecified amount.
Nobel Biocare doubles its 2nd-quarter profits as it reportedly fields interest – and at least 1 offer worth $2.3 billion – from potential acquirers.
Here's a look at some of the top Wall Street stories for medical device companies this week: Will Medtronic follow Walgreen and abandon inversion in Covidien deal?; ElectroCore seeks commercial partners for non-invasive headache tech; Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO; Activist investor battles on over ConMed as shareholders vote approaches; Medtronic's Q1 earnings beat The Street on modest sales bump
Allergan reportedly solicits Salix Pharmaceuticals in a bid to stymie the $53 billion hostile takeover move by Valeant Pharmaceuticals and Pershing Square Capital Management.
Ocular Therapeutix raises $74.8 million after under-writers grab another 750,000 shares in the company's initial public offering.
Bedford, Mass.-based Ocular Therapeutix (NSDQ:OCUL) raised $74.8 million though its initial public offering after underwriters fully exercised an over-allotment option to snag additional shares.